- Overweight
Orforglipron: What is it and what can it do?
Written by: Editors
Modified on:
Orforglipron is the latest advancement in weight-loss medication from Eli Lilly, the company also known for Mounjaro. Significant strides have been made in the medical field in addressing obesity and overweight conditions. New medications, such as GLP-1 agonists, have proven effective in supporting weight loss. Meanwhile, extensive research into new treatments continues. Orforglipron is currently in the research phase and, at the time of writing, has not yet been approved or made available. What distinguishes this medication from existing treatments for obesity or overweight conditions? In this article, we explore its mechanism of action, potential benefits, and the research findings to date.
Orforglipron is a new oral treatment for obesity and overweight conditions. It is part of a new generation of non-peptide GLP-1 receptor agonists that can be taken in tablet form. Its mechanism of action is similar to that of existing injectable weight-loss medications but offers the convenience of being administered orally. Currently, the medication remains in the clinical research phase and has not yet been approved or made available in the European Union. It is also being investigated as a potential treatment for type 2 diabetes. We will provide updates as new findings or insights from these studies emerge.
How does Orforglipron work?
The active ingredient, orforglipron, binds to GLP-1 receptors and stimulates insulin production in the pancreas when required. Additionally, it slows gastric emptying, suppresses appetite, and enhances the feeling of satiety. As a result, individuals consume less food, which can aid in the weight-loss process. Orforglipron is a GLP-1 medication in tablet form with a chemical structure distinct from the existing injectable variants.
The benefits of Orforglipron
The mechanism of this new medication for obesity and overweight conditions is broadly similar to that of existing weight-loss drugs. Some potential benefits include:
- Tablet form: Individuals who are uncomfortable with or have an aversion to injections may prefer tablets.
- Minimal impact from food: Food appears to have little influence on its absorption, meaning it does not necessarily need to be taken on an empty or full stomach.
- Absorption in the intestines: Research suggests that the medication is absorbed in the intestines.
Preliminary research results
Manufacturer Eli Lilly has reported promising results thus far. In a phase 2 study involving adults with obesity or overweight conditions, the highest dose tested resulted in an average weight loss of approximately 12% over the study period. Additionally, improvements were observed in blood pressure, cholesterol, triglycerides, and inflammatory markers. This suggests that the medication may offer benefits beyond weight loss. However, these findings are preliminary, and further research is required to confirm its safety, efficacy, and optimal dosage.
Possible side effects of Orforglipron
As with any medication, Orforglipron may cause side effects. Since it is still in the research phase, not all potential side effects are yet known. To date, the following side effects have been reported:
- Diarrhoea
- Nausea and vomiting
- Constipation
- Digestive disturbances in the stomach, oesophagus, or small intestine
These side effects are consistent with those observed in existing GLP-1 agonists.
Conclusion
Orforglipron has shown promising results in various stages of research. However, further studies are necessary to determine its true effectiveness and safety. This tablet-form medication may appeal to individuals who prefer to avoid injections.
Doctoronline is closely monitoring developments surrounding this new medication. As soon as new information becomes available, we will share it.